ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1023

Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors
Abstract Number: 0354

Factors Associated with Health Information Technology Use Among United States Adults with Arthritis from 2012-2017: Analysis of the National Health Interview Survey
Abstract Number: 2152

Factors Associated with Health-related Quality of Life in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – a Cross Sectional Analysis from the SAPHO-CNO Study
Abstract Number: 0420

Factors Associated with Infant Feeding Behaviors Among Women with Systemic Rheumatic Diseases
Abstract Number: 0366

Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Abstract Number: 0729

Factors Associated with Pauci-immune Glomerulonephritis in Patients Undergoing Renal Biopsy with Positive ANCA Results
Abstract Number: 1106

Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Abstract Number: 0722

Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis
Abstract Number: 1441

Factors Associated with the Evolution of Degenerative Spinal Lesions in Axial Spondyloarthritis: 10-Year Follow-up of the DESIR Cohort
Abstract Number: 0538

Factors Associated with Upadacitinib Persistence and Risk Minimization Measures in Patients with Rheumatic Diseases in a Real-world Setting. UPAreal Study
Abstract Number: 2324

Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients with and Without First-degree Relatives with Psoriatic Disease
Abstract Number: 0436

Family Planning in Rheumatology: A Single Center Quality Improvement Project
Abstract Number: 1690

FAPI-PET/CT as a Predictor of Accelerated Lung Function Deterioration in Systemic Sclerosis Related Interstitial Lung Disease (ILD): Preliminary-interim Analysis from a Confirmatory Risk Factor Study
Abstract Number: 0352

Fast-tracking Axial Spondyloarthritis Diagnosis: A Novel Approach to Public Health Advocacy and Awareness
Abstract Number: 0053

Fasting Reduces an IL-17+/IFNg+ T Helper Cell-inducing Gut Pathobiont in Patients with Rheumatoid Arthritis
Abstract Number: 2329

Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment
Abstract Number: 2228

Feasibility, Safety, and Application for Clinical Indication and Research Purposes of Synovial Tissue Analysis in Rheumatoid Arthritis
Abstract Number: 2447

Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
Abstract Number: 1997

Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15
Abstract Number: 2165

Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease
Abstract Number: 2298

Fibroblast-driven Ttek Activation May Drive Acinar Cell Dysfunction in Sjögren’s Disease, Prior to Lymphocytic Infiltration
Abstract Number: 2292

Fibroblasts with High Expression of CD74 Promote Lymphocytes Infiltration in Salivary Gland in Sjӧgren’s Disease
Abstract Number: 1225

Fibromyalgia as a Potential Initial Presentation for Autoimmune Conditions
Abstract Number: 1220

Fibromyalgia’s Under-Representation in Rheumatology Literature: A Ten-Year Analysis of Disease-Specific Article Distribution
Abstract Number: 1332

Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
Abstract Number: PP09

Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Abstract Number: 0786

First Analyses of Transcriptomic Changes in the Skin of SSc Patients upon CD19-targeting CAR T Cell Therapy
Abstract Number: 1134

First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158
Abstract Number: 0057

Flow Cytometry of Cells Within Induced Sputum from Individuals At-Risk for RA Reveals Relative Expansion of Small Macrophages
Abstract Number: 1862

Folate Receptor β CAR-Tregs Induce Monocyte Apoptosis and Immune Polarization: Potential for Therapeutic Application in Rheumatoid Arthritis
Abstract Number: 0776

Follicular Dendritic Cell PD-L1 Expression Promotes Autoreactive Germinal Center Formation
Abstract Number: 1344

Forced Vital Capacity Trajectories and Risk of Lung Transplant and ILD-Related Mortality Among Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1835

FoxP3Hi CTLA4+ ICOS+ Regulatory T Cells Are Expanded in Patients with Sarcoidosis but Not Systemic Sclerosis or IgG4-Related Disease
Abstract Number: 1748

Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level
Abstract Number: 2129

Fracture Risk Assessment Tool (FRAX®) Scores Predict Mortality in Community-Dwelling Elderlies
Abstract Number: 2137

Fractures Post Lung Transplant: A Retrospective Cohort Study Conducted at an International Transplant Center
Abstract Number: 0059

Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance
Abstract Number: 2140

Frailty Is Associated with Lower Bone Mineral Density in US Veterans with Rheumatoid Arthritis
Abstract Number: 2512

French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy
Abstract Number: 0153

Frequencies and Rates of All-Cause Emergency Visits and Hospitalizations in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review
Abstract Number: 2417

Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America
Abstract Number: 1229

Frequency of Fibromyalgia Using Validated Measures in a Sample of Patients with Psoriatic Arthritis and Impact on Disease: A Cross-Sectional Multinational Study
Abstract Number: 2513

Frequency, Diagnosis, and Management of Polymyalgia Rheumatica in Germany – Database Analysis of Medical Insurance Data
Abstract Number: 1315

From Presentation to Publication: Tracking the Publication Rate of Abstracts Presented at American College of Rheumatology Convergence Conference in the Years 2015 and 2018

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].